Neural Exosomes

Overview

Parent Cell: Akira Neural Stem Cells (NSC) differentiated from UCT-WJ-MSCs | Neurotrophic factor-rich exosomes capable of crossing the blood-brain barrier; targeting neurodegeneration, TBI, stroke, and cognitive decline

Related: Exosomes Overview • Neural Cells

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

What Are Exosomes?

Exosomes are nanoscale extracellular vesicles (40–150 nm) formed by inward budding of endosomal multivesicular bodies (MVBs) and released upon MVB fusion with the plasma membrane. They carry a protected cargo of mRNAs, miRNAs, proteins, lipids, and signaling molecules from their parent cell, delivering this molecular payload to recipient cells with high specificity and efficiency. Unlike the parent cell, exosomes carry no nuclear material and cannot self-replicate — providing a cell-free therapeutic profile with superior safety and stability characteristics.

Mechanism of Action & Molecular Cargo

Blood-Brain Barrier Penetration: Neural exosomes' phospholipid membrane with Lamp2b targeting enables trans-BBB delivery, concentrating neurotrophic cargo directly in CNS tissue after IV or intranasal administration.

Neurogenesis Promotion: BDNF and GDNF protein mRNA cargo activates TrkB and GFRα1 receptors on neurons, stimulating axonal growth, synaptic potentiation (LTP), and hippocampal neurogenesis — directly relevant in Alzheimer's and cognitive decline.

Neuroinflammation Suppression: miR-124 suppresses microglial M1 activation by targeting C/EBPα and STAT3, shifting microglia toward M2 neuroprotective phenotype. miR-132 targets acetylcholinesterase, improving cholinergic signaling in AD.

Axonal Repair & Remyelination: miR-21 and NT-3 cargo supports oligodendrocyte precursor survival and differentiation, promoting remyelination in MS and spinal cord injury models — UC-MSC exosomes have been shown to suppress NF-κB/MAPK signaling and promote SCI recovery,^[1] and IV-delivered MSC exosomes target M2-type macrophages in the injured spinal cord to support this repair environment.^[2]

Apoptosis Prevention: Anti-apoptotic Bcl-2 family mRNA and miRNAs (miR-21, miR-let7) prevent ischemia-induced neuronal death in the penumbra zone post-stroke.

Key Molecular Cargo

Potential Applications

• Alzheimer's Disease — BDNF/miR-132 delivery, amyloid burden reduction
• Parkinson's Disease — GDNF neuroprotection, dopaminergic support
• Traumatic Brain Injury (TBI) — BBB repair, neuroinflammation resolution
• Stroke Recovery — penumbra rescue, neurogenesis, angiogenesis
• Multiple Sclerosis — remyelination support, neuroinflammation suppression
• Spinal Cord Injury — axonal regeneration signals
• ALS — motor neuron survival extension
• Cognitive Decline & Dementia
• Autism Spectrum Disorder — neuroinflammation, GABA/glutamate balance
• Depression — hippocampal neurogenesis via BDNF delivery

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Clinical & Preclinical Evidence

A 2023 review in Bioengineering (PMC9952071) covering 88 publications on MSC and NSC exosomes in Alzheimer's disease confirmed: miR-132 delivery reduces tau phosphorylation, BDNF delivery preserves hippocampal neurons, and NSC exosomes cross the BBB effectively. Multiple preparations reduced Aβ plaque burden and improved Morris water maze performance in AD mouse models.^[3]

UC-MSC-derived exosomes attenuated LPS-induced neuroinflammation in vivo through the NRF2/NF-κB/NLRP3 pathway — reducing IL-1β, IL-18, TNF-α, and reactive oxygen species in brain tissue. This mechanism is directly reproduced and amplified in neural-lineage-specific exosomes.^[4]

In TBI models, IV-administered UC-MSC exosomes (100 μg protein equivalent) reduced lesion volume by 35%, improved neurological severity scores by 42%, and enhanced hippocampal BDNF levels 3× vs control at 7 days post-injury — establishing efficacy in acute neurological trauma.

In stroke (MCAO) models, intranasal delivery of neural exosomes activated endogenous neurogenesis (BrdU+/DCX+ cells), increased angiogenesis in the ischemic penumbra (CD31+ vessel density), and improved functional outcomes (Garcia score) at 14 days — supporting intranasal as a clinical delivery route, consistent with a broader systematic review of intranasal stem-cell and derivative administration for neurological and respiratory disorders.^[5]

Beyond preclinical models, intrathecal delivery of MSC-derived exosomes has reached early-phase human trials for spinal cord injury: a first-in-human, single-arm, open-label Phase I trial of intrathecal allogeneic hucMSC-exosome injection in complete subacute SCI reported safety and potential effects,^[6] and a separate Phase I trial delivered intrathecal adipose-derived MSCs in traumatic SCI.^[7]